Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

29.65
+0.15000.51%
Post-market: 29.650.00000.00%19:30 EDT
Volume:1.49M
Turnover:44.08M
Market Cap:5.11B
PE:13.50
High:29.78
Open:29.50
Low:29.15
Close:29.50
52wk High:30.96
52wk Low:19.69
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.95
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:3.91
PE(LYR):12.89

Loading ...

Earning Preview: ACADIA Pharmaceuticals this quarter’s revenue is expected to increase by 17.56%, and institutional views are bullish

Earnings Agent
·
Apr 30

Acadia Pharmaceuticals announces virtual annual shareholder meeting

Reuters
·
Apr 29

ACADIA Pharmaceuticals publishes 2025 annual report

Reuters
·
Apr 29

Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 28

Acadia presents Phase 4 LOTUS real-world DAYBUE data in Rett syndrome at AAN 2026

Reuters
·
Apr 17

Bank of America Securities Remains a Buy on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 16

Acadia Pharmaceuticals to report first-quarter results after US market close

Reuters
·
Apr 16

Did DAYBUE STIX’s Flexible Rett Formulation Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative?

Simply Wall St.
·
Apr 16

A Look At Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX US Launch

Simply Wall St.
·
Apr 11

RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 09

Acadia Pharmaceuticals announces Daybue Stix available in U.S.

TIPRANKS
·
Apr 07

ACADIA Pharmaceuticals Announces Daybue® Stix (Trofinetide) Is NOW Broadly Available in the United States for the Treatment of Rett Syndrome

THOMSON REUTERS
·
Apr 07

RBC Capital Adjusts ACADIA Pharmaceuticals PT to $29 From $30, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

ACADIA Pharmaceuticals Shares Rise After BofA Upgrade

MT Newswires Live
·
Mar 26

BofA Securities Upgrades ACADIA Pharmaceuticals to Buy From Neutral, Price Target is $29

MT Newswires Live
·
Mar 25

ACADIA Pharmaceuticals Raised to Buy From Neutral by B of A Securities

Dow Jones
·
Mar 25

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Reuters
·
Mar 25

Acadia Pharmaceuticals' Remlifanserin Shows Favorable Setup Ahead of Phase 2 Data, RBC Says

MT Newswires Live
·
Mar 24

RBC Capital Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Mar 24

ACADIA Pharmaceuticals director Jonathan Poole files initial beneficial ownership statement

Reuters
·
Mar 21